HomeCVAC • NASDAQ
add
CureVac BV
Previous close
$2.77
Day range
$2.84 - $3.15
Year range
$2.22 - $12.36
Market cap
702.08M USD
Avg Volume
750.94K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | — | — |
Net income | -86.65M | 32.71% |
Net profit margin | — | — |
Earnings per share | -0.39 | 42.65% |
EBITDA | -77.99M | -31.98% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 402.45M | -18.83% |
Total assets | 788.25M | -8.39% |
Total liabilities | — | — |
Total equity | — | — |
Shares outstanding | — | — |
Price to book | — | — |
Return on assets | — | — |
Return on capital | — | — |
Cash Flow
Net change in cash
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -86.65M | 32.71% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | -1.41M | -104.23% |
Net change in cash | — | — |
Free cash flow | -27.94M | 66.22% |
About
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA. Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee. CureVac has approximately 375 employees since May 2018.
At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, caused by infection with the SARS-CoV-2 virus. Clinical trials for the CureVac COVID-19 Vaccine began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company. In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy. In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology. Wikipedia
Founded
2000
Website
Employees
999
